TNYA

SEC source: 0001193125-25-284999 · ownership.xml · nonDerivative · entry 1

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,971

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024.

F2 · balance_after: Includes 50,470 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-25-284996 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 299,666

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

F2 · balance_after: Includes 211,275 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-25-284997 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,926

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · balance_after: Includes 85,838 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-109915 · ownership.xml · nonDerivative · entry 3

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,338

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 54,220 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-109915 · ownership.xml · nonDerivative · entry 2

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,060

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 58,907 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-109915 · ownership.xml · nonDerivative · entry 1

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,777

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 60,844 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001667937-25-000006 · ownership.xml · nonDerivative · entry 3

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,792

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 219,881 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001667937-25-000006 · ownership.xml · nonDerivative · entry 2

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 307,712

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 233,318 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001667937-25-000006 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,605

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 243,943 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001868494-25-000006 · ownership.xml · nonDerivative · entry 3

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,803

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 93,757 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001868494-25-000006 · ownership.xml · nonDerivative · entry 2

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,640

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 98,757 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001868494-25-000006 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,248

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 103,132 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 6,000 shares of common stock acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan on June 10, 2025.

SEC source: 0000950170-25-079948 · ownership.xml · derivative · entry 1

Burroughs Amy L. · CIK 0001872564 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-079947 · ownership.xml · derivative · entry 1

GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-079946 · ownership.xml · derivative · entry 1

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-079949 · ownership.xml · derivative · entry 1

Walsh Jeffrey T. · CIK 0001578251 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-079941 · ownership.xml · derivative · entry 1

Parschauer Karah Herdman · CIK 0001677455 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-079943 · ownership.xml · derivative · entry 1

Lee June · CIK 0001696493 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-079950 · ownership.xml · derivative · entry 1

Stehman-Breen Catherine · CIK 0001702233 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-079944 · ownership.xml · derivative · entry 1

Srivastava Deepak · CIK 0001868501 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,400

Underlying: Common Stock · 107,400 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0000950170-25-073825 · ownership.xml · nonDerivative · entry 1

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,300

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024.

F2 · balance_after: Includes 62,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-073823 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,325

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

F2 · balance_after: Includes 259,568 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-073824 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,856

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · balance_after: Includes 107,507 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036774 · ownership.xml · nonDerivative · entry 3

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,690

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 66,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036774 · ownership.xml · nonDerivative · entry 2

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,535

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 67,938 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036774 · ownership.xml · nonDerivative · entry 1

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,155

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on October 15, 2022.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 69,345 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036770 · ownership.xml · nonDerivative · entry 2

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,514

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 268,174 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036770 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,461

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 278,799 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036772 · ownership.xml · nonDerivative · entry 3

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,793

F5 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F6 · balance_after: Includes 115,426 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036772 · ownership.xml · nonDerivative · entry 2

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,391

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4 · balance_after: Includes 119,801 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-036772 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,464

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 131,051 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 3,409 shares of common stock acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 10, 2024.

SEC source: 0000950170-25-035789 · ownership.xml · derivative · entry 5

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 17,857,142

Underlying: Common Stock · 17,857,142 shares

Expires 2026-06-30

F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant").

F7 · derivative.exercise_date: Each Series B Warrant is immediately exercisable (subject to certain beneficial ownership limitations).

F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners").

F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-035789 · ownership.xml · derivative · entry 4

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 35,714,284

Underlying: Common Stock · 35,714,284 shares

Expires 2030-03-04

F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant").

F6 · derivative.exercise_date: Each Series A Warrant is immediately exercisable (subject to certain beneficial ownership limitations).

F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners").

F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-035789 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 49,313,559

F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant").

F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners").

F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-035788 · ownership.xml · derivative · entry 5

GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 17,857,142

Underlying: Common Stock · 17,857,142 shares

Expires 2026-06-30

F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant").

F7 · derivative.exercise_date: Each Series B Warrant is immediately exercisable (subject to certain beneficial ownership limitations).

F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners").

F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-035788 · ownership.xml · derivative · entry 4

GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 35,714,284

Underlying: Common Stock · 35,714,284 shares

Expires 2030-03-04

F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant").

F6 · derivative.exercise_date: Each Series A Warrant is immediately exercisable (subject to certain beneficial ownership limitations).

F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners").

F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-035788 · ownership.xml · nonDerivative · entry 1

GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 49,313,559

F1 · price: Pursuant to an underwritten public offering, The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased units (the "Units") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock", and such shares, the "Shares"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a "Series A Warrant") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a "Series B Warrant").

F2 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners").

F3 · ownership.nature: (Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 9

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401,390

Underlying: Common Stock · 401,390 shares

Expires 2032-02-14

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F11 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 15, 2022, and the remaining shares vest in 48 equal monthly installments thereafter.

SEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 8

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 401,390 shares

Expires 2032-02-14

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F11 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 15, 2022, and the remaining shares vest in 48 equal monthly installments thereafter.

SEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 7

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,214

Underlying: Common Stock · 161,214 shares

Expires 2031-06-16

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F10 · derivative.exercise_date: 1/48th of the shares underying the option vested on July 17, 2021, and the remaining shares vest in 48 equal monthly installments thereafter.

SEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 6

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 161,214 shares

Expires 2031-06-16

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F10 · derivative.exercise_date: 1/48th of the shares underying the option vested on July 17, 2021, and the remaining shares vest in 48 equal monthly installments thereafter.

SEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 5

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353,271

Underlying: Common Stock · 353,271 shares

Expires 2031-02-26

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F7 · derivative.exercise_date: The shares underlying the option are fully vested and exercisable.

SEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 4

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 353,271 shares

Expires 2031-02-26

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F7 · derivative.exercise_date: The shares underlying the option are fully vested and exercisable.

SEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 3

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2035-03-05

F6 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

SEC source: 0000950170-25-016582 · ownership.xml · nonDerivative · entry 2

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,255

F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

F4 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the total number of shares subject to the restricted stock unit award on May 15, 2025, and 1/4th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

F5 · balance_after: Includes 294,424 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-016582 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,831

F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2025, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

F3 · balance_after: Includes 260,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000950170-25-010075 · ownership.xml · derivative · entry 11

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2034-02-22

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on January 24, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices equal to or greater than $3.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share, the closing price of the Issuer's common stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2016 Equity Incentive Plan or 2021 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F12 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 23, 2024, and the remaining shares vest in 48 equal monthly installments thereafter.

SEC source: 0000950170-25-010075 · ownership.xml · derivative · entry 10

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 215,000 shares

Expires 2034-02-22

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on January 24, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices equal to or greater than $3.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share, the closing price of the Issuer's common stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2016 Equity Incentive Plan or 2021 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F12 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 23, 2024, and the remaining shares vest in 48 equal monthly installments thereafter.

SEC source: 0000950170-25-010075 · ownership.xml · derivative · entry 9

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock · 205,000 shares

Expires 2033-02-14

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on January 24, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices equal to or greater than $3.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share, the closing price of the Issuer's common stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2016 Equity Incentive Plan or 2021 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F11 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 15, 2023, and the remaining shares vest in 48 equal monthly installments thereafter.

SEC source: 0000950170-25-010075 · ownership.xml · derivative · entry 8

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 205,000 shares

Expires 2033-02-14

F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on January 24, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices equal to or greater than $3.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share, the closing price of the Issuer's common stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2016 Equity Incentive Plan or 2021 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

F11 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 15, 2023, and the remaining shares vest in 48 equal monthly installments thereafter.